AR055095A1 - Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c - Google Patents
Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis cInfo
- Publication number
- AR055095A1 AR055095A1 ARP060103210A ARP060103210A AR055095A1 AR 055095 A1 AR055095 A1 AR 055095A1 AR P060103210 A ARP060103210 A AR P060103210A AR P060103210 A ARP060103210 A AR P060103210A AR 055095 A1 AR055095 A1 AR 055095A1
- Authority
- AR
- Argentina
- Prior art keywords
- hepatitis
- macrociclic
- inhibitors
- new
- virus replication
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Las realizaciones proveen compuestos de las formulas generales (1) a (8), así como composiciones que incluyen composiciones farmacéuticas que comprenden el compuesto de la presente. LAs realizaciones también proveen métodos de tratamiento, que incluyen métodos de tratar una infeccion por el virus de la hepatitis C y métodos de tratar la fibrosis hepática, que consisten en administrar a un individuo que lo necesita una cantidad eficaz de un compuesto o composicion de la presente.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70219505P | 2005-07-25 | 2005-07-25 | |
US72553305P | 2005-10-11 | 2005-10-11 | |
US78980006P | 2006-04-06 | 2006-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR055095A1 true AR055095A1 (es) | 2007-08-08 |
Family
ID=37433829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103210A AR055095A1 (es) | 2005-07-25 | 2006-07-25 | Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c |
Country Status (23)
Country | Link |
---|---|
US (4) | US20090148407A1 (es) |
EP (6) | EP2305696A3 (es) |
JP (2) | JP5249028B2 (es) |
KR (1) | KR101294467B1 (es) |
CN (2) | CN101263156A (es) |
AR (1) | AR055095A1 (es) |
AU (1) | AU2006276246B2 (es) |
BR (1) | BRPI0613962A2 (es) |
CA (1) | CA2615666C (es) |
CU (1) | CU23794B7 (es) |
EA (2) | EA019888B1 (es) |
EC (1) | ECSP088208A (es) |
GE (1) | GEP20105124B (es) |
IL (3) | IL221361A (es) |
MA (1) | MA29746B1 (es) |
MX (1) | MX2008001166A (es) |
MY (1) | MY148690A (es) |
NO (1) | NO20080875L (es) |
NZ (2) | NZ565059A (es) |
SG (1) | SG166791A1 (es) |
TN (1) | TNSN08022A1 (es) |
TW (1) | TW200740851A (es) |
WO (1) | WO2007015824A2 (es) |
Families Citing this family (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060446A1 (en) | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
EP2305696A3 (en) * | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
KR20080056295A (ko) | 2005-10-11 | 2008-06-20 | 인터뮨, 인크. | C형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법 |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
JP2009542698A (ja) * | 2006-07-07 | 2009-12-03 | ギリアード サイエンシーズ, インコーポレイテッド | 抗ウイルスホスフィナート化合物 |
EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
ES2448494T3 (es) | 2006-07-13 | 2014-03-14 | Achillion Pharmaceuticals, Inc. | Péptidos de 4-amino-4-oxobutanoilo en calidad de inhibidores de la replicación viral |
US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN101568336B (zh) * | 2006-11-16 | 2012-07-04 | 百时美施贵宝公司 | 大环肽在制备丙型肝炎病毒抑制剂中的用途 |
WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008067981A2 (en) * | 2006-12-04 | 2008-06-12 | Dsm Ip Assets B.V. | Whole-cell catalytic system comprising a hydantoinase, a racemase and a carbamoylase |
CA2667654C (en) * | 2006-12-18 | 2016-12-13 | Intermune, Inc. | Method of providing pirfenidone therapy to a patient |
EP2111227A1 (en) * | 2007-01-08 | 2009-10-28 | Phenomix Corporation | Macrocyclic hepatitis c protease inhibitors |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US20090155209A1 (en) | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
AP2009005057A0 (en) | 2007-05-10 | 2009-12-31 | Array Biopharma Inc | Novel peptide inhibitors of hepatitis c virus replication |
AR067442A1 (es) * | 2007-06-29 | 2009-10-14 | Gilead Sciences Inc | Compuestos antivirales |
TW200918524A (en) * | 2007-06-29 | 2009-05-01 | Gilead Sciences Inc | Antiviral compounds |
US8513186B2 (en) * | 2007-06-29 | 2013-08-20 | Gilead Sciences, Inc. | Antiviral compounds |
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
WO2009053828A2 (en) * | 2007-10-22 | 2009-04-30 | Enanta Pharmaceuticals, Inc. | P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors |
US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
EP2224942A4 (en) | 2007-12-05 | 2012-01-25 | Enanta Pharm Inc | FLUORATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS |
WO2009073719A1 (en) | 2007-12-05 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl derivatives |
CN101951769B (zh) | 2007-12-21 | 2014-12-31 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
CN101951770B (zh) * | 2007-12-21 | 2014-12-31 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
AU2015224437B2 (en) * | 2007-12-21 | 2017-05-25 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US8309685B2 (en) * | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
CN101903391B (zh) * | 2007-12-21 | 2013-04-03 | 弗·哈夫曼-拉罗切有限公司 | 大环化合物的制备方法 |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
WO2009099596A2 (en) * | 2008-02-04 | 2009-08-13 | Idenix Pharamaceuticals, Inc. | Macrocyclic serine protease inhibitors |
EP2268619A4 (en) | 2008-03-20 | 2012-04-04 | Enanta Pharm Inc | FLUORINATED MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS |
SI2276725T1 (sl) | 2008-04-11 | 2012-09-28 | Hoffmann La Roche | Novi rutenijevi kompleksi kot katalizatorji za metatezne reakcije |
AU2009249443A1 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20090285773A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009148923A1 (en) | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2009152051A1 (en) * | 2008-06-12 | 2009-12-17 | Phenomix Corporation | Synthesis of a macrocyclic hcv protease inhibitor |
KR101647520B1 (ko) * | 2008-08-07 | 2016-08-10 | 에프. 호프만-라 로슈 아게 | 거대환식 화합물의 제조 방법 |
US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP3025727A1 (en) | 2008-10-02 | 2016-06-01 | The J. David Gladstone Institutes | Methods of treating liver disease |
EA201170441A1 (ru) * | 2008-10-15 | 2012-05-30 | Интермьюн, Инк. | Терапевтические противовирусные пептиды |
EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
KR101634833B1 (ko) | 2008-10-22 | 2016-06-29 | 어레이 바이오파마 인크. | TRK 키나아제 억제제로서 치환된 피라졸로[1,5a] 피리미딘 화합물 |
US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
US7566729B1 (en) | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
EP2364309B1 (en) | 2008-12-10 | 2014-10-01 | Achillion Pharmaceuticals, Inc. | New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
EP2376514A2 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
NZ593647A (en) | 2008-12-23 | 2013-08-30 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
AU2010206543A1 (en) * | 2009-01-26 | 2011-07-07 | Intermune, Inc. | Methods for treating acute myocardial infarctions and associated disorders |
US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
EP2403860B1 (en) | 2009-03-04 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole as hcv polymerase inhibitors |
EP2417134B1 (en) | 2009-04-08 | 2017-05-17 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
CA2812683C (en) | 2009-09-25 | 2017-10-10 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
CN102712644A (zh) * | 2009-09-28 | 2012-10-03 | 豪夫迈·罗氏有限公司 | 丙肝病毒复制的新型大环抑制剂 |
EA201290128A1 (ru) * | 2009-09-28 | 2013-01-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликации вируса гепатита с |
WO2011042217A1 (en) | 2009-10-09 | 2011-04-14 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
WO2011049908A2 (en) * | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
US8084475B2 (en) * | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
CN102822175A (zh) | 2009-12-18 | 2012-12-12 | 埃迪尼克斯医药公司 | 5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂 |
US8933110B2 (en) * | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
SG188957A1 (en) | 2010-01-25 | 2013-05-31 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
SG183344A1 (en) | 2010-02-16 | 2012-09-27 | Api Corp | Method for producing 1-amino-1-alkoxycarbonyl-2-vinylcyclopropane |
WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
US8324212B2 (en) * | 2010-02-25 | 2012-12-04 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
JP5872539B2 (ja) | 2010-03-31 | 2016-03-01 | ギリアド ファーマセット エルエルシー | プリンヌクレオシドホスホルアミダート |
AU2011235112B2 (en) | 2010-03-31 | 2015-07-09 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
CN102947265B (zh) | 2010-04-19 | 2015-07-29 | 奥瑞泽恩基因组学股份有限公司 | 赖氨酸特异性脱甲基酶-1抑制剂及其应用 |
EP2918588B1 (en) * | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
WO2012013728A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
CN103153330B (zh) | 2010-08-12 | 2017-08-18 | 美国科技环球有限公司 | 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用 |
WO2012040167A1 (en) * | 2010-09-21 | 2012-03-29 | Enanta Pharmaceuticals, Inc. | Macrocyclic proline derived hcv serine protease inhibitors |
US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
US9890198B2 (en) | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
WO2012092411A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
AU2012212269B2 (en) | 2011-01-31 | 2016-05-19 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
EP3981395A1 (en) | 2011-02-08 | 2022-04-13 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
NZ623396A (en) | 2011-09-16 | 2016-07-29 | Gilead Pharmasset Llc | Methods for treating hcv |
EP3736265A1 (en) | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
RS58475B1 (sr) | 2011-10-20 | 2019-04-30 | Oryzon Genomics Sa | Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
EP2802595B1 (en) | 2012-01-11 | 2016-01-06 | AbbVie Inc. | Processes for making hcv protease inhibitors |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
JP2015533124A (ja) | 2012-10-08 | 2015-11-19 | アッヴィ・インコーポレイテッド | Hcvプロテアーゼ阻害剤を作製するのに有用な化合物 |
JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
JP2016501848A (ja) * | 2012-11-16 | 2016-01-21 | アデレード リサーチ アンド イノヴェーション プロプライエタリー リミテッド | 大環状化合物及びその使用 |
LT2950786T (lt) | 2013-01-31 | 2020-03-10 | Gilead Pharmasset Llc | Dviejų antivirusinių junginių preparatų kompozicija |
WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
CN105408317A (zh) | 2013-03-14 | 2016-03-16 | 艾其林医药公司 | 用于生产Sovaprevir的方法 |
US9006423B2 (en) | 2013-03-15 | 2015-04-14 | Achillion Pharmaceuticals Inc. | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
WO2014145600A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof |
WO2014144087A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Sovaprevir polymorphs and methods of manufacture thereof |
ES2735355T3 (es) | 2013-03-15 | 2019-12-18 | Gilead Sciences Inc | Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C |
NZ716840A (en) | 2013-08-27 | 2017-06-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
NZ722927A (en) | 2014-01-10 | 2022-07-29 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
EP3114122A1 (en) | 2014-03-05 | 2017-01-11 | Idenix Pharmaceuticals LLC | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
DK3699181T3 (da) | 2014-11-16 | 2023-03-20 | Array Biopharma Inc | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat |
BR112018008357A2 (pt) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas |
CN107043405B (zh) * | 2016-02-05 | 2021-11-19 | 爱博新药研发(上海)有限公司 | 多环杂环化合物的晶型、其制备方法、应用及组合物 |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
RU2751767C2 (ru) | 2016-04-04 | 2021-07-16 | Локсо Онколоджи, Инк. | Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида |
LT3458456T (lt) | 2016-05-18 | 2021-02-25 | Loxo Oncology, Inc. | (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamido gavimas |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
CN108299506A (zh) * | 2018-01-29 | 2018-07-20 | 中国科学院成都有机化学有限公司 | N-杂环卡宾钌络合物及其制备方法和用途 |
GB201818750D0 (en) * | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
CA3223714A1 (en) | 2021-06-23 | 2022-12-29 | Oskari KARJALAINEN | Process for the preparation of a cyp11a1 inhibitor and intermediates thereof |
Family Cites Families (206)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3547119A (en) | 1967-12-08 | 1970-12-15 | Baxter Laboratories Inc | Catheter assembly |
US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
US4311137A (en) | 1980-04-30 | 1982-01-19 | Sherwood Medical Industries Inc. | Infusion device |
US4531937A (en) | 1983-01-24 | 1985-07-30 | Pacesetter Systems, Inc. | Introducer catheter apparatus and method of use |
CS263951B1 (en) | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
ATE108794T1 (de) | 1985-05-15 | 1994-08-15 | Wellcome Found | Therapeutische nucleoside und deren herstellung. |
US4806347A (en) | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
US4755173A (en) | 1986-02-25 | 1988-07-05 | Pacesetter Infusion, Ltd. | Soft cannula subcutaneous injection set |
CS264222B1 (en) | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
US5082659A (en) | 1986-10-06 | 1992-01-21 | Board Of Regents, The University Of Texas System | Methods and compositions employing interferon-gamma |
US5190751A (en) | 1987-01-20 | 1993-03-02 | Schering Corporation | Treatment of certain leukemias with a combination of gamma interferon and alpha interferon |
ES2039276T3 (es) | 1987-01-20 | 1993-09-16 | Schering Corporation | Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias. |
WO1988009673A1 (en) | 1987-06-02 | 1988-12-15 | Schering Corporation | Treatment of chronic type b hepatitis with a combination of recombinant human alpha and gamma interferons |
US4904770A (en) | 1988-03-24 | 1990-02-27 | Bristol-Myers Company | Production of 2',3'-dideoxy-2',3'-didehydronucleosides |
US5130421A (en) | 1988-03-24 | 1992-07-14 | Bristol-Myers Company | Production of 2',3'-dideoxy-2',3'-didehydronucleosides |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US5552558A (en) | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5232928A (en) * | 1989-07-25 | 1993-08-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Tetrahydroisoquinoline amides |
GB8918806D0 (en) | 1989-08-17 | 1989-09-27 | Shell Int Research | Chiral compounds,their preparation and use |
US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
DE10399025I2 (de) | 1990-09-14 | 2007-11-08 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
DE4121214A1 (de) | 1991-06-27 | 1993-01-14 | Bayer Ag | 7-azaisoindolinyl-chinolon- und -naphthyridoncarbonsaeure-derivate |
US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
DE69334250D1 (de) | 1992-12-29 | 2009-01-29 | Abbott Lab | Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern |
US5545143A (en) | 1993-01-21 | 1996-08-13 | T. S. I. Medical | Device for subcutaneous medication delivery |
ES2174915T3 (es) | 1993-11-10 | 2002-11-16 | Enzon Inc | Productos de conjugacion mejorados de un interferon con un polimero. |
US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
US6693072B2 (en) * | 1994-06-02 | 2004-02-17 | Aventis Pharmaceuticals Inc. | Elastase inhibitors |
US5500208A (en) | 1994-06-07 | 1996-03-19 | The Procter & Gamble Company | Oral compositions comprising a novel tripeptide |
US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
IL116730A0 (en) | 1995-01-13 | 1996-05-14 | Amgen Inc | Chemically modified interferon |
US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
US5908121A (en) | 1996-03-11 | 1999-06-01 | Dardashti; Shahriar | Adjustable display assembly |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
AU2933797A (en) | 1996-05-10 | 1997-12-05 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
PL194025B1 (pl) | 1996-10-18 | 2007-04-30 | Vertex Pharma | Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
US6232333B1 (en) | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
AU7127298A (en) | 1997-04-14 | 1998-11-11 | Emory University | Serine protease inhibitors |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
ES2234144T3 (es) | 1997-08-11 | 2005-06-16 | Boehringer Ingelheim (Canada) Ltd. | Analogos de peptidos inhibidores de la hepatitis c. |
ATE291032T1 (de) | 1997-08-11 | 2005-04-15 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptide |
US6767991B1 (en) * | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
US6172046B1 (en) | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
JP4690545B2 (ja) | 1998-03-31 | 2011-06-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子 |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
US7157430B2 (en) | 1998-10-22 | 2007-01-02 | Idun Pharmaceuticals, Inc. | (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
WO2000066623A2 (en) | 1999-05-04 | 2000-11-09 | Boehringer Ingelheim (Canada) Ltd. | Surrogate cell-based system and method for assaying the activity of hepatitis c virus ns3 protease |
US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
ES2240446T3 (es) | 2000-04-03 | 2005-10-16 | Vertex Pharma | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. |
DE60137207D1 (de) * | 2000-04-05 | 2009-02-12 | Schering Corp | Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen |
SK14952002A3 (sk) * | 2000-04-19 | 2003-03-04 | Schering Corporation | Makrocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie |
US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
PL206255B1 (pl) * | 2000-07-21 | 2010-07-30 | Dendreon Corporationdendreon Corporation | Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii |
JP3889708B2 (ja) * | 2000-11-20 | 2007-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎トリペプチド阻害剤 |
EP1408986B1 (en) * | 2001-05-08 | 2008-09-24 | Yale University | Proteomimetic compounds and methods |
CN100402549C (zh) * | 2001-07-11 | 2008-07-16 | 沃泰克斯药物股份有限公司 | 桥连二环的丝氨酸蛋白酶抑制剂 |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
CA2370400A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
NZ561851A (en) | 2002-04-11 | 2009-05-31 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease |
WO2003091264A2 (en) * | 2002-04-26 | 2003-11-06 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
US20040033970A1 (en) | 2002-04-30 | 2004-02-19 | Clark Richard F. | Antibacterial compounds with improved pharmacokinetic profiles |
AU2003299519A1 (en) | 2002-05-20 | 2004-05-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2004043339A2 (en) * | 2002-05-20 | 2004-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
EP1506000B9 (en) * | 2002-05-20 | 2011-08-31 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis c virus inhibitors |
US20040033959A1 (en) * | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
US20040138109A1 (en) * | 2002-09-30 | 2004-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Potent inhibitor of HCV serine protease |
PL199412B1 (pl) * | 2002-10-15 | 2008-09-30 | Boehringer Ingelheim Int | Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7601709B2 (en) * | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
KR100940619B1 (ko) | 2003-02-07 | 2010-02-05 | 이난타 파마슈티칼스, 인코포레이티드 | 마크로사이클릭 씨형 간염 세린 단백효소 억제제 |
US20040180815A1 (en) | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
JP4550824B2 (ja) * | 2003-03-05 | 2010-09-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎抑制化合物 |
UY28240A1 (es) | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
CA2520886A1 (en) * | 2003-04-02 | 2004-11-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
JP4231524B2 (ja) * | 2003-04-10 | 2009-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大環状化合物の製造方法 |
JP2007523833A (ja) | 2003-04-10 | 2007-08-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ルテニウム錯体触媒メタセシス反応による大環状化合物の製造方法 |
TW200510391A (en) * | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
ES2386161T3 (es) | 2003-04-16 | 2012-08-10 | Bristol-Myers Squibb Company | Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
EP2143727B1 (en) * | 2003-04-18 | 2015-01-21 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
WO2004096285A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
ATE490788T1 (de) | 2003-04-25 | 2010-12-15 | Gilead Sciences Inc | Antivirale phosphonate analoge |
US20040229848A1 (en) | 2003-05-05 | 2004-11-18 | Hans-Ulrich Demuth | Glutaminyl based DP IV-inhibitors |
US7273851B2 (en) | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
PE20050374A1 (es) * | 2003-09-05 | 2005-05-30 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc |
AU2004274468B2 (en) * | 2003-09-18 | 2009-07-23 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
MXPA06003141A (es) * | 2003-09-22 | 2006-06-05 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c. |
JP4525982B2 (ja) * | 2003-09-26 | 2010-08-18 | シェーリング コーポレイション | C型肝炎ウイルスのns3セリンプロテアーゼの大環状インヒビター |
KR20120010278A (ko) * | 2003-10-10 | 2012-02-02 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의 억제제 |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
PL1680137T3 (pl) * | 2003-10-14 | 2013-04-30 | F Hoffmann La Roche Ltd | Makrocykliczny kwas karboksylowy i związek acylosulfonamidowy jako inhibitor replikacji HCV |
CA2551074A1 (en) * | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Hcv ns3-ns4a protease resistance mutants |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP2007532479A (ja) * | 2003-11-20 | 2007-11-15 | シェーリング コーポレイション | C型肝炎ウイルスns3プロテアーゼの脱ペプチド化インヒビター |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) * | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2005053735A1 (en) * | 2003-11-20 | 2005-06-16 | Boehringer Ingelheim International Gmbh | Method of removing transition metals, especially from metathesis reaction products |
DE602004019973D1 (de) | 2003-12-08 | 2009-04-23 | Boehringer Ingelheim Int | Abtrennung von ruthenium-nebenprodukten durch behandlung mit überkritischen flüssigkeiten |
AU2004298498B2 (en) * | 2003-12-11 | 2008-09-11 | Schering Corporation | Inhibitors of hepatitis C virus NS3/NS4a serine protease |
ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
EP1711514B1 (en) | 2004-01-28 | 2008-12-03 | Boehringer Ingelheim International GmbH | Method of removing transition metals from reaction solutions comprising transition metal byproducts |
ES2336009T3 (es) * | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
WO2005077969A2 (en) | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
KR20060124725A (ko) * | 2004-02-27 | 2006-12-05 | 쉐링 코포레이션 | C형 간염 바이러스 ns3 프로테아제의 억제제 |
EP1939213B1 (en) * | 2004-02-27 | 2010-08-25 | Schering Corporation | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease |
JP4874227B2 (ja) * | 2004-02-27 | 2012-02-15 | シェーリング コーポレイション | C型肝炎ウイルスのns3セリンプロテアーゼインヒビターとしての環状p4’sを有する新規ケトアミド |
US7816326B2 (en) * | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
WO2005087730A1 (en) | 2004-02-27 | 2005-09-22 | Schering Corporation | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease |
AU2005224092A1 (en) | 2004-03-15 | 2005-09-29 | Boehringer Ingelheim International, Gmbh | Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis C viral infections |
WO2005095403A2 (en) * | 2004-03-30 | 2005-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
WO2005097820A1 (en) | 2004-04-06 | 2005-10-20 | Korea Research Institute Of Bioscience And Biotechnology | Peptides for inhibiting mdm2 function |
CN1984922A (zh) * | 2004-05-20 | 2007-06-20 | 先灵公司 | 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸 |
US7514557B2 (en) | 2004-05-25 | 2009-04-07 | Boehringer Ingelheim International Gmbh | Process for preparing acyclic HCV protease inhibitors |
WO2006000085A1 (en) | 2004-06-28 | 2006-01-05 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
US7939538B2 (en) * | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
DE102004033312A1 (de) * | 2004-07-08 | 2006-01-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren |
AP2461A (en) * | 2004-07-16 | 2012-09-14 | Gilead Sciences Inc | Antiviral compounds |
JP4914355B2 (ja) * | 2004-07-20 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビターペプチド類似体 |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
CN101068828A (zh) * | 2004-08-27 | 2007-11-07 | 先灵公司 | 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物 |
CA2577831A1 (en) | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic hcv protease inhibitors |
EP1794179A1 (en) * | 2004-09-17 | 2007-06-13 | Boehringer Ingelheim International Gmbh | Ring-closing metathesis process in supercritical fluid |
EP2332527A3 (en) | 2004-10-20 | 2011-11-16 | Resverlogix Corp. | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases |
DE102005002336A1 (de) * | 2005-01-17 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7524831B2 (en) | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
AU2006220887B2 (en) | 2005-03-04 | 2010-11-04 | The Rockefeller University | Infectious, chimeric Hepatitis C Virus, methods of producing the same and methods of use thereof |
KR101514953B1 (ko) | 2005-03-08 | 2015-04-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 매크로사이클릭 화합물의 제조방법 |
WO2006113942A2 (en) | 2005-04-20 | 2006-10-26 | Schering Corporation | Method of inhibiting cathepsin activity |
CA2606195C (en) * | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
EP1899368A2 (en) | 2005-05-26 | 2008-03-19 | Schering Corporation | Interferon-igg fusion |
US20060276404A1 (en) | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
AU2006252553B2 (en) | 2005-06-02 | 2012-03-29 | Merck Sharp & Dohme Corp. | Combination of HCV protease inhibitors with a surfactant |
US20060276407A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
US20060276405A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis C |
WO2006130688A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Compounds for inhibiting cathepsin activity |
WO2006130553A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors |
US20070021351A1 (en) | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
US20060281689A1 (en) | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
US20060275366A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
PL1891089T3 (pl) | 2005-06-02 | 2015-05-29 | Merck Sharp & Dohme | Inhibitory proteazy HCV w połączeniu z pokarmem |
US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
US7601686B2 (en) * | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
TW200738742A (en) | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
EP2305696A3 (en) * | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
WO2007016476A2 (en) | 2005-08-01 | 2007-02-08 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
CA2617679A1 (en) | 2005-08-02 | 2007-02-08 | Steve Lyons | Inhibitors of serine proteases |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
KR20080056295A (ko) * | 2005-10-11 | 2008-06-20 | 인터뮨, 인크. | C형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법 |
US7772183B2 (en) * | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) * | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7705138B2 (en) * | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
CA2641859A1 (en) | 2006-02-09 | 2007-08-16 | Schering Corporation | Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto |
MX2008011868A (es) | 2006-03-16 | 2008-12-15 | Vertex Pharma | Inhibidores deuterados de la proteasa de la hepatitis c. |
US20070287664A1 (en) | 2006-03-23 | 2007-12-13 | Schering Corporation | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto |
NZ571826A (en) | 2006-04-11 | 2012-01-12 | Novartis Ag | HCV/HIV inhibitors and their uses |
US9526769B2 (en) | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US20080187516A1 (en) | 2006-06-06 | 2008-08-07 | Ying Sun | Acyclic oximyl hepatitis c protease inhibitors |
US7728148B2 (en) * | 2006-06-06 | 2010-06-01 | Enanta Pharmaceuticals, Inc. | Acyclic oximyl hepatitis C protease inhibitors |
US20090203008A1 (en) | 2006-06-08 | 2009-08-13 | Ludmerer Steven W | Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples |
UY30437A1 (es) | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
EP2049474B1 (en) * | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
ES2448494T3 (es) * | 2006-07-13 | 2014-03-14 | Achillion Pharmaceuticals, Inc. | Péptidos de 4-amino-4-oxobutanoilo en calidad de inhibidores de la replicación viral |
US20090155209A1 (en) * | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
AP2009005057A0 (en) | 2007-05-10 | 2009-12-31 | Array Biopharma Inc | Novel peptide inhibitors of hepatitis c virus replication |
AU2009249443A1 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
EA201170441A1 (ru) * | 2008-10-15 | 2012-05-30 | Интермьюн, Инк. | Терапевтические противовирусные пептиды |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
EA201290128A1 (ru) * | 2009-09-28 | 2013-01-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликации вируса гепатита с |
CN102712644A (zh) * | 2009-09-28 | 2012-10-03 | 豪夫迈·罗氏有限公司 | 丙肝病毒复制的新型大环抑制剂 |
WO2011041551A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
WO2011146401A1 (en) | 2010-05-17 | 2011-11-24 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
-
2006
- 2006-07-17 EP EP11151028A patent/EP2305696A3/en not_active Withdrawn
- 2006-07-17 EP EP09164272A patent/EP2103623A3/en not_active Withdrawn
- 2006-07-17 JP JP2008523949A patent/JP5249028B2/ja active Active
- 2006-07-17 MX MX2008001166A patent/MX2008001166A/es unknown
- 2006-07-17 CN CNA2006800272902A patent/CN101263156A/zh active Pending
- 2006-07-17 CN CN2012102790551A patent/CN102816170A/zh active Pending
- 2006-07-17 KR KR1020087004379A patent/KR101294467B1/ko active IP Right Grant
- 2006-07-17 SG SG201007886-3A patent/SG166791A1/en unknown
- 2006-07-17 BR BRPI0613962-0A patent/BRPI0613962A2/pt not_active Application Discontinuation
- 2006-07-17 CA CA2615666A patent/CA2615666C/en not_active Expired - Fee Related
- 2006-07-17 NZ NZ565059A patent/NZ565059A/en not_active IP Right Cessation
- 2006-07-17 GE GEAP200610529A patent/GEP20105124B/en unknown
- 2006-07-17 EP EP11151031A patent/EP2305697A3/en not_active Withdrawn
- 2006-07-17 EP EP11151014A patent/EP2305695A3/en not_active Ceased
- 2006-07-17 EP EP06800088A patent/EP1924594A2/en not_active Withdrawn
- 2006-07-17 EP EP11151034A patent/EP2305698A3/en not_active Withdrawn
- 2006-07-17 US US11/996,902 patent/US20090148407A1/en not_active Abandoned
- 2006-07-17 EA EA201170969A patent/EA019888B1/ru not_active IP Right Cessation
- 2006-07-17 NZ NZ594105A patent/NZ594105A/xx not_active IP Right Cessation
- 2006-07-17 AU AU2006276246A patent/AU2006276246B2/en not_active Ceased
- 2006-07-17 WO PCT/US2006/027738 patent/WO2007015824A2/en active Application Filing
- 2006-07-17 EA EA200800413A patent/EA015752B1/ru not_active IP Right Cessation
- 2006-07-21 US US11/491,126 patent/US7829665B2/en not_active Expired - Fee Related
- 2006-07-21 MY MYPI20063490A patent/MY148690A/en unknown
- 2006-07-25 AR ARP060103210A patent/AR055095A1/es unknown
- 2006-07-25 TW TW095127122A patent/TW200740851A/zh unknown
-
2008
- 2008-01-09 IL IL221361A patent/IL221361A/en not_active IP Right Cessation
- 2008-01-09 IL IL188693A patent/IL188693A/en not_active IP Right Cessation
- 2008-01-18 TN TNP2008000022A patent/TNSN08022A1/en unknown
- 2008-01-23 CU CU20080010A patent/CU23794B7/es not_active IP Right Cessation
- 2008-02-19 NO NO20080875A patent/NO20080875L/no not_active Application Discontinuation
- 2008-02-20 EC EC2008008208A patent/ECSP088208A/es unknown
- 2008-02-22 MA MA30670A patent/MA29746B1/fr unknown
- 2008-04-18 US US12/106,234 patent/US20090169510A1/en not_active Abandoned
-
2012
- 2012-04-19 US US13/450,885 patent/US8299021B2/en not_active Expired - Fee Related
- 2012-05-22 JP JP2012116528A patent/JP2012214476A/ja not_active Withdrawn
- 2012-08-08 IL IL221361A patent/IL221361A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR055095A1 (es) | Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c | |
ECSP066959A (es) | Compuestos macrociclicos como inhibidores de la replicación viral | |
ECSP099780A (es) | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c | |
ECSP066570A (es) | Ácidos carboxílicos macrocíclicos y acilsulfonamidas como inhibidores de replicación del hcv | |
ECSP10010612A (es) | Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c | |
ECSP099792A (es) | Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c | |
CU20090112A6 (es) | Compuestos macrocíclicos como inhibidores de la replicación viral | |
MX2009008439A (es) | Nuevos inhibidores de la replicacion del virus de hepatitis c. | |
WO2007047146A3 (en) | Inhibitors of viral replication | |
WO2008005511A8 (en) | Novel inhibitors of hepatitis c virus replication | |
MX2012003171A (es) | Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c. | |
WO2009134616A8 (en) | Novel inhibitors of hepatitis c virus replication | |
CU23602A3 (es) | Compuestos macrocíclicos como inhibidores de la replicación viral | |
UA95455C2 (ru) | Макроциклические ингибиторы репликации вируса гепатита с | |
CU20090182A7 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
CU20090188A7 (es) | Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c | |
TW200611905A (en) | Macrocyclic compounds as inhibitors of viral replication |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |